Pharmatek Adds Spray Drying Capabilities

Pharmatek Laboratories, Inc. has added spray drying to its drug formulation and manufacturing capabilities with the purchase of a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture. This technology can be used for both oral and parenteral dosage forms.

“Spray drying is an integral technology in Pharmatek’s toolkit for formulating insoluble compounds. The high degree of control and reduced process steps afforded by this process offer a number of advantages over other formulation techniques: enhanced robustness and reproducibility, and the ability to control and create uniform particle size and stabilize volatile and thermo-sensitive compounds,” said Jeffrey Bibbs, chief executive officer and chief scientific officer of Pharmatek.